Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases

Ekaterina Dadachova, Arturo Casadevall

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The field of infectious diseases is in crisis and there is a need for strategies that can facilitate the rapid development of new antimicrobial agents. Radioimmunotherapy (RIT), a therapeutic modality originally developed for cancer treatment, has recently been suggested as a novel therapy for the treatment of a variety of infectious diseases. Because specific antibodies are used in RIT as delivery vehicles of cytocidal radiation, their molecular weight influences the nonspecific accumulation in infectious foci and blood clearance, and their affinity-specific accumulation of antibodies in infectious foci. Like the problems encountered in oncology, relevant variables in the development of RIT of infectious diseases include target antigen-shedding; delivering radionuclides to infectious foci in organs, abscesses, granulomas, heart and brain, and potential safety concerns. Dadachova and Casadevall anticipate that RIT can be developed for many types of infectious diseases, including microbes resistant to conventional antimicrobial therapy and agents of biological warfare.

Original languageEnglish (US)
Pages (from-to)1075-1084
Number of pages10
JournalExpert Opinion on Drug Delivery
Volume2
Issue number6
DOIs
StatePublished - Nov 2005

Fingerprint

Radioimmunotherapy
Communicable Diseases
Antibodies
Anti-Infective Agents
Biological Warfare
Therapeutics
Granuloma
Radioisotopes
Abscess
Molecular Weight
Radiation
Safety
Antigens
Brain
Neoplasms

Keywords

  • Infectious diseases
  • Monoclonal antibodies
  • Radioimmunotherapy
  • Scintigraphic imaging

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases. / Dadachova, Ekaterina; Casadevall, Arturo.

In: Expert Opinion on Drug Delivery, Vol. 2, No. 6, 11.2005, p. 1075-1084.

Research output: Contribution to journalArticle

Dadachova, Ekaterina ; Casadevall, Arturo. / Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases. In: Expert Opinion on Drug Delivery. 2005 ; Vol. 2, No. 6. pp. 1075-1084.
@article{c119b94dde3442c19660da2f6df3292a,
title = "Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases",
abstract = "The field of infectious diseases is in crisis and there is a need for strategies that can facilitate the rapid development of new antimicrobial agents. Radioimmunotherapy (RIT), a therapeutic modality originally developed for cancer treatment, has recently been suggested as a novel therapy for the treatment of a variety of infectious diseases. Because specific antibodies are used in RIT as delivery vehicles of cytocidal radiation, their molecular weight influences the nonspecific accumulation in infectious foci and blood clearance, and their affinity-specific accumulation of antibodies in infectious foci. Like the problems encountered in oncology, relevant variables in the development of RIT of infectious diseases include target antigen-shedding; delivering radionuclides to infectious foci in organs, abscesses, granulomas, heart and brain, and potential safety concerns. Dadachova and Casadevall anticipate that RIT can be developed for many types of infectious diseases, including microbes resistant to conventional antimicrobial therapy and agents of biological warfare.",
keywords = "Infectious diseases, Monoclonal antibodies, Radioimmunotherapy, Scintigraphic imaging",
author = "Ekaterina Dadachova and Arturo Casadevall",
year = "2005",
month = "11",
doi = "10.1517/17425247.2.6.1075",
language = "English (US)",
volume = "2",
pages = "1075--1084",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases

AU - Dadachova, Ekaterina

AU - Casadevall, Arturo

PY - 2005/11

Y1 - 2005/11

N2 - The field of infectious diseases is in crisis and there is a need for strategies that can facilitate the rapid development of new antimicrobial agents. Radioimmunotherapy (RIT), a therapeutic modality originally developed for cancer treatment, has recently been suggested as a novel therapy for the treatment of a variety of infectious diseases. Because specific antibodies are used in RIT as delivery vehicles of cytocidal radiation, their molecular weight influences the nonspecific accumulation in infectious foci and blood clearance, and their affinity-specific accumulation of antibodies in infectious foci. Like the problems encountered in oncology, relevant variables in the development of RIT of infectious diseases include target antigen-shedding; delivering radionuclides to infectious foci in organs, abscesses, granulomas, heart and brain, and potential safety concerns. Dadachova and Casadevall anticipate that RIT can be developed for many types of infectious diseases, including microbes resistant to conventional antimicrobial therapy and agents of biological warfare.

AB - The field of infectious diseases is in crisis and there is a need for strategies that can facilitate the rapid development of new antimicrobial agents. Radioimmunotherapy (RIT), a therapeutic modality originally developed for cancer treatment, has recently been suggested as a novel therapy for the treatment of a variety of infectious diseases. Because specific antibodies are used in RIT as delivery vehicles of cytocidal radiation, their molecular weight influences the nonspecific accumulation in infectious foci and blood clearance, and their affinity-specific accumulation of antibodies in infectious foci. Like the problems encountered in oncology, relevant variables in the development of RIT of infectious diseases include target antigen-shedding; delivering radionuclides to infectious foci in organs, abscesses, granulomas, heart and brain, and potential safety concerns. Dadachova and Casadevall anticipate that RIT can be developed for many types of infectious diseases, including microbes resistant to conventional antimicrobial therapy and agents of biological warfare.

KW - Infectious diseases

KW - Monoclonal antibodies

KW - Radioimmunotherapy

KW - Scintigraphic imaging

UR - http://www.scopus.com/inward/record.url?scp=28244453324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28244453324&partnerID=8YFLogxK

U2 - 10.1517/17425247.2.6.1075

DO - 10.1517/17425247.2.6.1075

M3 - Article

C2 - 16296810

AN - SCOPUS:28244453324

VL - 2

SP - 1075

EP - 1084

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 6

ER -